Antiviral Therapy

Papers
(The TQCC of Antiviral Therapy is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Evaluation of doravirine-based regimen population target in a large Italian clinical center24
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection23
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective14
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients14
The making of the one pill—Developing single tablet regimens for HIV and for HCV13
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting13
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation12
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)–infected patients12
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants12
Commentary: John C. Martin (1951–2021)10
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts10
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study9
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity8
Real-life findings on the impact of the COVID-19 pandemic on HIV care8
A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir8
Tenofovir alafenamide fumarate7
Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort stud6
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway6
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir6
A favipiravir-induced angioedema and urticaria in a COVID-19 patient6
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report6
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach5
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis5
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review5
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical s4
Oseltamivir and acute hepatitis, reality association or coincidence?4
Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)4
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine4
The transformation of HIV therapy: One pill once a day4
Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database4
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort4
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study4
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults4
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial4
Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis4
0.026473045349121